{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:42:34Z","timestamp":1783629754415,"version":"3.55.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Current guidance from the American Diabetes Association recommends liver stiffness measurement (LSM) only when the Fibrosis-4 (FIB-4) index is elevated. However, LSM may provide additional valuable information compared with FIB-4, which is known to underperform in certain populations, such as individuals with type 2 diabetes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether liver fibrosis evaluated by LSM is associated with increased mortality in individuals with and without diabetes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included adult patients with complete vibration-controlled transient elastography (VCTE) and controlled attenuation parameter (CAP) data. Baseline data, including demographics and routine laboratory tests, were obtained from the 2017 to 2018 National Health and Nutrition Examination Survey and linked to data from the National Center for Health Statistics and National Death Index up to December 31, 2019. Patients with a history of liver disease other than metabolic dysfunction-associated steatotic liver disease were excluded. Data were analyzed from December 2024 to December 2025, accounting for the complex survey design using examination weights.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Liver disease based on CAP results and LSM by VCTE. CAP results 274 dB\/m or higher indicate a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and LSM results 9.7 kPa or higher indicate advanced liver fibrosis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n All-cause mortality. Mortality risk was expressed as hazard ratios (HRs) with 95% CIs calculated using Cox proportional hazards regression models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 4102 adult patients (mean [SEM] age, 47 [1] years; 50.7% female), were included in the study. The mean (SEM) body mass index (BMI), calculated as weight in kilograms divided by height in meters squared, was 29.5 (0.3). Diabetes was present in 14.5% of participants. After a mean (SEM) follow-up of 24 (2) months, 59 patients (1.4%) had died. Patients who died during follow-up vs those who did not were older (mean [SEM] age, 62 [3] years vs 47 [1] years;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), had a higher prevalence of diabetes (35.7% vs 14.2%;\n P<\/jats:italic>\n \u2009=\u2009.01), and were more likely to be of non-Hispanic White race (85.1% vs 62.7%,\n P<\/jats:italic>\n \u2009=\u2009.002). Increased risk of all-cause mortality was associated with the coexistence of diabetes with MASLD (adjusted hazard ratio [AHR], 2.77; 95% CI, 1.16-6.65;\n P<\/jats:italic>\n \u2009=\u2009.03) and diabetes with advanced liver fibrosis (AHR 6.41; 95% CI, 1.03-39.85;\n P<\/jats:italic>\n \u2009=\u2009.047). In patients with diabetes, LSM (AHR, 1.06; 95% CI, 1.04-1.09;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) but not FIB-4 index remained associated with all-cause mortality even after adjusting for other clinical variables, such as age, sex, BMI, and hemoglobin A\n 1c<\/jats:sub>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, LSM was an independent risk factor for all-cause mortality in individuals with diabetes, even after a relatively short follow-up. Implementing LSM to screen for liver fibrosis as part of routine diabetes management could aid in early identification of patients with high mortality risk.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0762","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:54Z","timestamp":1773847854000},"page":"e260762","source":"Crossref","is-referenced-by-count":2,"title":["Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes"],"prefix":"10.1001","volume":"9","author":[{"given":"Fernando","family":"Bril","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham"},{"name":"UAB Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ky","family":"Huynh","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameshwara Rao","family":"Bolla","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"4","key":"zoi260052r1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"zoi260052r2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes.","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi260052r3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/hbsn.2019.11.11","article-title":"Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change.","volume":"9","author":"Bril","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"zoi260052r4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf110","article-title":"Prevalence of MASLD in people with diabetes has decreased in the US, but rates of liver fibrosis are still on the rise.","volume":"9","author":"Bril","year":"2025","journal-title":"J Endocr Soc"},{"issue":"3","key":"zoi260052r5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/hep.30858","article-title":"Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease.","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"zoi260052r6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S.","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi260052r7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. a consensus report of the American Diabetes Association.","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"zoi260052r8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes.","volume":"43","author":"Bril","year":"2020","journal-title":"Diabetes Care"},{"issue":"17","key":"zoi260052r9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease.","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260052r10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"zoi260052r11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ajg.2010.18","article-title":"Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.","volume":"105","author":"Adams","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"zoi260052r12","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1111\/dom.15153","article-title":"Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).","volume":"25","author":"Collier","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"zoi260052r14","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/liv.16034","article-title":"Metabolic characteristics of patients with MetALD: Caveats of a new definition.","volume":"44","author":"Petrie","year":"2024","journal-title":"Liver Int"},{"issue":"1","key":"zoi260052r15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cgh.2021.12.029","article-title":"Prevalence of high-risk nonalcoholic steatohepatitis (NASH) in the United States: results from NHANES 2017-2018.","volume":"21","author":"Vilar-Gomez","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi260052r16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"zoi260052r17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"zoi260052r18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"zoi260052r19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/oby.23960","article-title":"Noninvasive tests to identify liver fibrosis in metabolic dysfunction-associated steatotic liver disease are affected by race.","volume":"32","author":"Bril","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"25","key":"zoi260052r20","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"zoi260052r22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"zoi260052r23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"zoi260052r24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","article-title":"Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications.","volume":"21","author":"Boursier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"zoi260052r25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/liv.13739","article-title":"Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.","volume":"38","author":"Bertot","year":"2018","journal-title":"Liver Int"},{"issue":"3","key":"zoi260052r26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"issue":"15","key":"zoi260052r27","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease.","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"zoi260052r28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease.","volume":"19","author":"Petta","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi260052r29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"zoi260052r30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD.","volume":"101","author":"Bril","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"zoi260052r31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes.","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi260052r32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","article-title":"Nonalcoholic fatty liver disease: The new complication of type 2 diabetes mellitus.","volume":"45","author":"Bril","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"zoi260052r33","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1210\/jc.2009-0541","article-title":"Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients.","volume":"94","author":"Petit","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"zoi260052r34","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1111\/j.1572-0241.2008.02188.x","article-title":"Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study.","volume":"103","author":"McKimmie","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"zoi260052r35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13098-015-0025-4","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c.","volume":"7","author":"Kwak","year":"2015","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"zoi260052r36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"zoi260052r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"zoi260052r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156066","article-title":"Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?","volume":"162","author":"Bril","year":"2025","journal-title":"Metabolism"},{"issue":"2","key":"zoi260052r39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/liv.15801","article-title":"Liver stiffness as a cornerstone in heart disease risk assessment.","volume":"44","author":"Boeckmans","year":"2024","journal-title":"Liver Int"},{"issue":"9","key":"zoi260052r40","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3748\/wjg.v22.i9.2647","article-title":"Ultrasound elastographic techniques in focal liver lesions.","volume":"22","author":"Conti","year":"2016","journal-title":"World J Gastroenterol"},{"key":"zoi260052r13","unstructured":"National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention, National Center for Health Statistics. Accessed February 5, 2026. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?Cycle=2017-2020"},{"key":"zoi260052r21","unstructured":"Linden? A. ASCVD: Stata module for computing ACC\/AHA 10-year risk for an initial hard atherosclerotic cardiovascular disease (ASCVD) event. Statistical Software Components S459162, Boston College Department of Economics. 2023. Accessed February 5, 2026. https:\/\/ideas.repec.org\/c\/boc\/bocode\/s459162.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846636\/bril_2026_oi_260052_1773255256.06216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:57Z","timestamp":1773847857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0762","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}